CryoPort (NASDAQ:CYRX) Director Sells $1,503,199.59 in Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Daniel Hancock sold 74,379 shares of CryoPort stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the sale, the director owned 69,052 shares in the company, valued at approximately $1,395,540.92. This represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Trading Down 2.2%

CYRX traded down $0.46 during trading on Thursday, reaching $20.10. 659,177 shares of the company’s stock were exchanged, compared to its average volume of 664,215. CryoPort, Inc. has a one year low of $7.61 and a one year high of $21.78. The stock has a market capitalization of $1.02 billion, a PE ratio of -20.72 and a beta of 1.89. The firm has a fifty day moving average price of $17.26 and a two-hundred day moving average price of $13.61.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. Sell-side analysts expect that CryoPort, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CYRX shares. Guggenheim increased their price objective on CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. KeyCorp lifted their target price on CryoPort from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Needham & Company LLC increased their price target on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Finally, BTIG Research increased their price target on CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.69.

Institutional Investors Weigh In On CryoPort

Several institutional investors and hedge funds have recently made changes to their positions in CYRX. Wellington Management Group LLP bought a new stake in CryoPort in the second quarter worth approximately $8,398,000. Roubaix Capital LLC boosted its holdings in shares of CryoPort by 12.4% during the 3rd quarter. Roubaix Capital LLC now owns 454,926 shares of the company’s stock worth $7,916,000 after buying an additional 50,148 shares in the last quarter. Royce & Associates LP bought a new position in shares of CryoPort during the 3rd quarter worth approximately $7,073,000. Russell Investments Group Ltd. boosted its holdings in shares of CryoPort by 376.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock worth $6,943,000 after buying an additional 315,343 shares in the last quarter. Finally, Squarepoint Ops LLC grew its position in shares of CryoPort by 685.1% during the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock worth $5,784,000 after buying an additional 321,497 shares during the period. Institutional investors own 92.90% of the company’s stock.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.